methyl (3R,4S,10S,13S)-4-[(3R)-3-(4-bromobenzoyl)oxybutyl]-3,4,10-trimethyl-1,2,3,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-13-carboxylate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: methyl (3R,4S,10S,13S)-4-[(3R)-3-(4-bromobenzoyl)oxybutyl]-3,4,10-trimethyl-1,2,3,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-13-carboxylate
• 化学式: C₃₃H₄₇BrO₄
• 分子量: 587.6
• InChiKey: YMMBBNZAHGRGBB-PLELJBLMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] COMPOUNDS FOR REDUCING GLUCOCORTICOIDS, AND METHODS OF TREATMENT THEREOF<br/>[FR] COMPOSÉS PERMETTANT DE RÉDUIRE LES GLUCOCORTICOÏDES, ET PROCÉDÉS DE TRAITEMENT ASSOCIÉS
  申请人：BIONICHE LIFE SCIENCES INC

  公开号：WO2014071506A1

  公开（公告）日：2014-05-15

  A method for reducing glucocorticoids in an animal in need thereof comprising the use of compounds of the formula (I), wherein the definitions for R', R1-R11 and n are as disclosed in the description. The compounds of formula (I) are for the treatment or prevention of a glucocorticoid-related disorder for maintaining bone density, maintaining and improving the immune system, treating Cushing' s syndrome, treating obesity, improving reproduction efficiency, treating metabolic disorder, treating hypertension, treating hyperglycemia, treating insulin resistance, treating type 2 diabetes, and/or aiding in cancer and immune therapies

  一种用于减少需要动物体内糖皮质激素的方法，包括使用式(I)的化合物，其中R'、R1-R11和n的定义如描述中所披露。式(I)的化合物用于治疗或预防与糖皮质激素相关的疾病，以维持骨密度、维护和改善免疫系统、治疗库欣综合征、治疗肥胖、提高生殖效率、治疗代谢紊乱、治疗高血压、治疗高血糖、治疗胰岛素抵抗、治疗2型糖尿病，和/或在癌症和免疫疗法中发挥作用。
• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
  申请人：CERULEAN PHARMA INC.

  公开号：US20130196945A1

  公开（公告）日：2013-08-01

  The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

  本发明涉及一种新型治疗环糊精含聚合物组成物，其设计为小分子治疗药物传递的载体以及其制药组合物。这些含环糊精聚合物可提高药物稳定性和溶解度，并在体内使用时减少小分子治疗药物的毒性。此外，通过从各种连接基团和靶向配体中进行选择，这些聚合物提供了治疗剂的控制释放方法。本发明还涉及使用所述治疗组成物治疗受试者的方法。本发明还涉及用于进行制药业务的方法，包括制造、许可或分发包含或涉及所述聚合物化合物的工具包。